Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
Qian Chu
100 participants
Jun 1, 2024
OBSERVATIONAL
Conditions
Summary
This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.
Eligibility
Inclusion Criteria5
- Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC
- Age ≥ 18 years
- Receiving definitive chemoradiotherapy
- Able and willing to complete electronic questionnaires
- Provided written informed consent
Exclusion Criteria3
- Severe comorbidities (heart, liver, kidney)
- Psychiatric illness or cognitive impairment
- Prior chest or mediastinal radiotherapy
Interventions
Participants complete the MDASI-LC and EQ-5D questionnaires electronically on a weekly basis during CRT and for 12 weeks after CRT. The data are used to evaluate symptom burden, symptom clusters, and symptom trajectories.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07131670